AstraZeneca and Ionis Think They Have A Best-In-Class PCSK9 Challenger To Novartis’s Leqvio

Study Shows 73% Reduction in LDL Cholesterol

 
• By Andrew McConaghie

AstraZeneca and Ionis believe they have a potential best-in-class PCSK9 inhibitor, but the product will have to impress in forthcoming pivotal trials to catch up with Novartis’s Leqvio.

Ionis HQ
The candidate is the latest to come out of Ionis' antisense oligonucleotide pipeline, and could be a strong challenger to Novartis's Leqvio. • Source: Ionis

More from Business

More from Scrip